Moreover, IFN-λ treatment has been shown to synergise with the kinase inhibitor sorafenib to inhibit Hepatocellular carcinoma cell growth and induce apoptosis (66), and a strong correlation between IFN-λ1, 2, and 3 producing cDC1 and beneficial outcomes in breast cancer has recently been described (63). Here, IFNL1 is linked to breast cancer.